How convenient isnt it? Lol

Italy... 8 Doses.

.First dose antibodies for 6 months.. technically 2 doses per year .. 8 Doses = 4 years..

Vaccine started in 2021Agenda .. completed 2025..

Guys the kids vaccine in India is going to be a “DNA” vaccine and is going to be given using a “patch” and not a syringe

Plus the efficacy rate is “66.6%”

This seems like it pretty much is the “mark of the beast” 😳🤷🏻‍♂️

The World Health Organization has just released a guiding document for a digital vaccine certificate that will be blockchain based. This will be used to implement a vaccine passport in every country. It’s funded by the Bill & Melinda Gate’s Foundation & Rockefeller Foundation.

This is the lyrics from famous celeb PRINCE song new world which was released in 1996 see what he was trying to reveal ....for your info lemme tell you he has been found dead in the elevator in a suspicious way and from post mortem report he died at 3.am which is famous for witchcraft and satanic blood sacrifice

This video just got taken down by IG. Please share it far and wide on telegram. - A senior doctors shared his perspective on vaccinating kids with the experimental vaccines.

Hospitals get a 20% Bonus if they admit you and give you new drugs called Remdesivir (Veklury), COVID-19 convalescent plasma, or baricitinib (Olumiant) in combination with Remdesivir.

By the way Remdesivir causes Acute Kidney failure which cause multiple Organ Failure which will lead to a ventilator and probably DEATH!!!

NCTAP claims are those that are eligible for the 20% add-on payment under Section 3710 of the CARES Act. Eligible claims have both of the following:

ICD-10-CM diagnosis code U07.1 (COVID-19)

ICD-10-PCS codes for remdesivir (Veklury), COVID-19 convalescent plasma, or baricitinib (Olumiant) in combination with remdesivir, as described below



CMS issued an Interim Final Rule with Comment Period that established the New COVID-19 Treatments Add-on Payment (NCTAP) under the Medicare Inpatient Prospective Payment System (IPPS). The NCTAP, designed to mitigate potential financial disincentives for hospitals to provide new COVID-19 treatments, is effective from November 2, 2020, until the end of the COVID-19 public health emergency (PHE). 
Through the NCTAP, the Medicare Program will provide an enhanced payment for eligible inpatient cases that use certain new products with current FDA approval or emergency use authorization (EUA) to treat COVID-19.

https://www.cms.gov/medicare/covid-19/new-covid-19-treatments-add-payment-nctap